Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial.
about
Antimalarial therapy selection for quinolone resistance among Escherichia coli in the absence of quinolone exposure, in tropical South AmericaA systematic review of knowledge, attitudes and beliefs about malaria among the South Asian populationSevere vivax malaria: a systematic review and meta-analysis of clinical studies since 1900The anaemia of Plasmodium vivax malariaThe impact of phenotypic and genotypic G6PD deficiency on risk of plasmodium vivax infection: a case-control study amongst Afghan refugees in PakistanEfficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studiesMultiple Origins of Mutations in the mdr1 Gene--A Putative Marker of Chloroquine Resistance in P. vivaxTowards a strategy for malaria in pregnancy in Afghanistan: analysis of clinical realities and women's perceptions of malaria and anaemiaA randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, PakistanResistance to therapies for infection by Plasmodium vivaxA systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and eliminationGlobal and local genetic diversity at two microsatellite loci in Plasmodium vivax parasites from Asia, Africa and South America.Field trial of three different Plasmodium vivax-detecting rapid diagnostic tests with and without evaporative cool box storage in AfghanistanDistribution of Plasmodium vivax pvdhfr and pvdhps alleles and their association with sulfadoxine-pyrimethamine treatment outcomes in Indonesia.In vivo Susceptibility of Plasmodium vivax to Chloroquine in Southeastern Iran.Prevalence of drug resistance associated mutations in Plasmodium vivax against sulphadoxine-pyrimethamine in southern PakistanPrevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan.Prevalence of antimalarial drug resistance mutations in Plasmodium vivax and P. falciparum from a malaria-endemic area of Pakistan.Existing antimalarial agents and malaria-treatment strategies.Prevalence of polymorphisms in antifolate drug resistance molecular marker genes pvdhfr and pvdhps in clinical isolates of Plasmodium vivax from Kolkata, India.Malaria treatment using novel nano-based drug delivery systems.Malaria "diagnosis" and diagnostics in Afghanistan.Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates.The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
P2860
Q21144279-7C4D3D27-011A-45EB-BB5C-E2CF582D9053Q26753105-8193834D-7450-434F-BD27-994FF9958A48Q26853034-17154812-C548-4659-A3A9-77BA7CBA9A7EQ27026970-ABCF564F-4D24-4FB5-AD94-6216671E219EQ28474079-AD885BA3-E73A-4089-AD5D-D2BF7ED4C636Q28535686-592B7EFE-F796-4FE8-9576-0ADFB8DF00DCQ28550721-2B0B3DEF-9F56-40BD-9CFF-3DACE1FF2773Q28607891-460A91F3-C030-4DEB-933D-794331F1BD03Q33358051-98F4DDC2-7105-4A72-A1DA-CDED7372C11FQ33481576-DFD5B617-7772-4C97-8C96-87AC74878163Q33517961-3B0C718F-3D6F-40D1-99CD-6F6CAB48D4C2Q33828657-8BE0D641-6D42-442C-B6A6-09C9346CD144Q34177472-E868CFAF-B618-47C2-9A16-30E511DF2F3EQ34354870-BA7B600F-4083-4FE5-96C9-EAE8F3B059A6Q35121981-E4E7DC47-E8A5-4D79-9143-48ABCC157525Q35784129-4F6F2131-A248-41C4-90C0-FCE62A6BCE58Q36311473-78871EE0-C2A9-45BF-BB2A-A1F2C89B07F5Q37070636-2169CA7A-B009-4D0B-8B87-8BADCB2C8122Q37155111-8667F7A6-1B82-4616-AEF6-3A693DB11198Q37462462-922B3890-F102-436F-A37C-B900ECED0064Q37492591-71C7529B-5D81-4B58-A319-6A80ACB97E70Q37544364-648144CF-B0D4-451A-9482-E8FE7755BFD6Q39122575-C2A9C7D5-3252-4D34-BC7B-6360AFD2055EQ39394789-6A9FE488-430B-4C33-9A11-00FCCE5C2145Q41940244-8852DDC6-7B17-49B7-B51A-ACBB60C9BC1CQ56338338-2529B5DD-3A98-41E2-B9FC-A96B5076A281
P2860
Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sulfadoxine-pyrimethamine, chl ...... a randomized controlled trial.
@en
type
label
Sulfadoxine-pyrimethamine, chl ...... a randomized controlled trial.
@en
prefLabel
Sulfadoxine-pyrimethamine, chl ...... a randomized controlled trial.
@en
P2093
P921
P356
P1476
Sulfadoxine-pyrimethamine, chl ...... a randomized controlled trial
@en
P2093
Eveline Klinkenberg
M Anwar Hasan
M Hanif Safi
M Ismail Mayan
Toby Leslie
P304
P356
10.1001/JAMA.297.20.2201
P407
P577
2007-05-01T00:00:00Z